DelMar Pharma presents promising preclinical data on VAL-083's potential to treat GBM
DelMar announced promising data on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme. The study's in vivo results demonstrate VAL-083 is effective against GBM in significantly extending survival time. April 20, 2015